Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 11, 2024
Daily News
October 11, 2024
- JaDHA Creates Hypothetical Case Collection to Push Two-Stage Approval of SaMD
October 11, 2024
- Asahi Kasei Offshoot to Develop Cancer Vaccine Using Proprietary DDS Base
October 11, 2024
- Ono Snags Worldwide Rights to LigaChem’s ADC Assets
October 11, 2024
- Incubation JV of Takeda, Astellas, SMBC Boots Up in Japan
October 11, 2024
- MHLW Asks for Ramp Up of HPV Vaccines after 5-Fold Rise in Demand
October 11, 2024
- Opdivo Approved for 1st Line Bladder Cancer Use in Taiwan: Ono
October 11, 2024
- EFPIA Chief Sees Positive Signal from Japan Policymakers, Calls for Consistency
October 11, 2024
- MHLW Orders Label Revision for Systemic NSAIDs
October 11, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…